atorvastatin has been researched along with Stroke in 237 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 107 (45.15) | 29.6817 |
| 2010's | 103 (43.46) | 24.3611 |
| 2020's | 27 (11.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, J; Choi, JH; Choi, KH; Choi, SH; Guallar, E; Gwon, HC; Hahn, JY; Kang, D; Kang, M; Kim, J; Lee, JM; Park, H; Park, TK; Song, YB; Yang, JH | 1 |
| Fang, F; Fang, Z; Li, J; Li, X; Li, Y; Wang, J; Wang, X | 1 |
| Chan, ECY; Soh, XQ; Tan, DS | 1 |
| Li, X; Yang, Q; Yang, Y | 1 |
| Amarenco, P; Bath, PM; Chen, W; Gao, Y; Han, S; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, T; Wang, Y; Yang, Y; Zhao, X | 1 |
| Ahn, CM; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yang, TH; Yoon, J | 1 |
| Chen, H; Hu, Y; Qin, X; Wang, M; Wang, S; Wu, J; Wu, T; Wu, Y; Yang, R; Yu, H | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
| Gong, X; Li, J; Lou, M; Luo, Z; Sun, J; Yan, S; Zhao, Y; Zhou, H; Zhou, Y | 1 |
| Betterton, RD; Davis, TP; Lochhead, JJ; Moreno-Rodriguez, VM; Ronaldson, PT; Stanton, JA; Williams, EI | 1 |
| Ahn, CM; Cho, HJ; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yoon, J | 1 |
| Salami, M; Soheili, M | 1 |
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Fujii, T; Ikari, Y; Murakami, T; Nakano, M; Nakazawa, G; Ohno, Y; Shinozaki, N; Yoshimachi, F | 1 |
| Amarenco, P; Callahan, A; DeMicco, D; Fayyad, R; Goldstein, LB; Laskey, R; Sillesen, H; Szarek, M; Welch, KM | 1 |
| Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M | 1 |
| Hoang, T; Kim, J | 1 |
| Barkoudah, E; Klein, JP; Mueller, AA; Tarter, LL; Vaidya, A | 1 |
| Spence, JD | 2 |
| Amarenco, P; Callahan, A; Goldstein, LB; Sillesen, H; Szarek, M; Welch, KM | 1 |
| Han, YC; Hou, Y; Sun, J; Wang, HY; Xu, QL; Zhang, DQ | 1 |
| Chen, J; Chen, R; Huang, Y; Shang, W; Shi, G; Zhang, C; Zhang, L; Zhang, P; Zhang, X | 1 |
| Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C | 1 |
| Salayandia, VM; Thompson, JF; Torbey, M; Yang, LY; Yang, Y | 1 |
| Ghafouri-Fard, S; Ghiasian, M; Khazaei, M; Khosravi, M; Mazaheri, S; Mazdeh, M; Taheri, M | 1 |
| Bolek, T; Galajda, P; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J; Vádelová, Ľ | 1 |
| Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN | 1 |
| Gao, Y; Liu, C; Yu, Y; Zhu, C | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Cameron, SJ; Doyle, A; Mix, D; Parsons, MR; Stoner, MC | 1 |
| Faizi, M; Khodagholi, F; Naderi, N; Nasoohi, S; Nikseresht, S; Simani, L | 1 |
| Ferreira, J; Giugliano, RP; Huber, K; Keech, A; Lewis, BS; Murphy, SA; Pedersen, TR; Pineda, AL; Sabatine, MS; Sever, PS; Somaratne, R; Tokgozoglu, SL | 1 |
| Andrés Marín, N; Antigüedad-Muñoz, J; Arenaza Choperena, G; de la Riva, P; Fernández-Eulate, G; Martínez Zabaleta, M; Moreno Valladares, M; Muñoz Lopetegi, A | 1 |
| Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK | 1 |
| Cao, L; Chen, X; Ding, Y; Dong, Z; He, L; Li, Q; Peng, C; Ren, H; Shen, Y; Yi, X; Zhou, D | 1 |
| Pitts-Tucker, T; Small, J | 1 |
| Ho, YF; Lin, FJ; Lin, HW | 1 |
| Davda, N; Osman, C | 1 |
| Aras, Y; Bagci-Onder, T; Erdag, E; Genc, C; Izgi, N; Tahta, A | 1 |
| Dalugama, C; Gawarammana, IB | 1 |
| Chen, L; Chen, X; Peng, Z; Yang, H; Yang, Q; Zhuang, X | 1 |
| Alvarez-Mendez, A; Beamonte-Vela, BN; García Carretero, R; Silvano-Cocinero, JD | 1 |
| Chouksey, D; Dani, R; Dube, M; Dubey, A | 1 |
| Li, S; Li, SH; Li, YS; Liu, XJ; Shi, CH; Song, B; Xu, YM | 1 |
| Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H | 1 |
| Kang, X; Li, X; Lv, H; Wang, D; Zhang, G; Zhang, L; Zhang, Q | 1 |
| Chao, HC; Chiang, CS; Kuo, CH; Lee, TH; Tang, SC; Yang, SY | 1 |
| Haas, MRC; Haas, NL; Nicholson, A | 1 |
| Delgado, G; Naves, M | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Bordet, R; Darteil, R; Duriez, P; Gautier, S; Hanf, R; Laprais, M; Ouk, T; Potey, C; Staels, B | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Albers, GW; Tai, WA | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Amarenco, P; Callahan, A; Campese, VM; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Wilson, DJ; Zivin, JA | 1 |
| Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Abdel-Rahman, I; Murphy, C | 1 |
| Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC | 1 |
| Fabiny, A | 1 |
| Dippel, DW; Scheele, M; van den Meiracker, AH; Versmissen, J | 1 |
| Guo, J; He, L; Li, J; Qin, F; Wu, B; Zhang, S; Zhou, D; Zhou, M | 1 |
| Berezowski, V; Bordet, R; Gautier, S; Ouk, T; Petrault, M; Petrault, O; Potey, C; Salleron, J | 1 |
| Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Konstantara, F; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tziomalos, K | 1 |
| Cheon, SY; Cho, KJ; Kim, GW | 1 |
| Chen, Y; Geng, J; Li, Y; Lin, Y; Mu, Z; Pan, Y; Shi, G; Song, Y; Sun, Y; Xu, Q; Yang, GY; Yu, L | 1 |
| Li, X; Pan, Y; Wang, X; Yang, J | 1 |
| Iijima, K; Imazeki, R; Kohara, S; Mizuma, A; Ohnuki, Y; Shimizu, M; Takizawa, S; Uesugi, T | 1 |
| Breker, DA; Gao, Z; Huang, Y; Li, Y; Mu, X; Zhang, J | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Acha-Salazar, O; Larrosa-Campo, D; Novo-Robledo, F; Oterino, A; Palacio, E; Revilla, M; Viadero-Cervera, R | 1 |
| Arnao, V; Corpora, F; Della Corte, V; Di Bona, D; Di Raimondo, D; Iacopino, DG; Maida, C; Maugeri, R; Pecoraro, R; Pinto, A; Simonetta, I; Tuttolomondo, A | 1 |
| Gao, JH; Gao, XP; Pan, SY | 1 |
| Bai, XD; Dila, NM; Hu, L; Li, YM; Liu, LY; Mao, JP; Yang, XY; Yue, YH; Zhang, HJ | 1 |
| Cao, JJ; Guerci, A; Pollack, S; Reichek, N; Roth, M; Waheed, S | 1 |
| Al Danaf, J; Duffy, D; Panakos, A; Ragupathi, L; Valentino, M; Whellan, D | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Alboim, C; Almeida, AP; Barbosa, RR; Berwanger, O; Carmona, MJ; Damiani, L; de Barros E Silva, PG; de Oliveira Filho, JB; Devereaux, PJ; Dracoulakis, MD; Figueiredo, EL; Filho, HV; Gonzales, B; Hajjar, LA; Ikeoka, DT; Kodama, AA; Kruel, CD; Lopes, RD; Maia, LN; Paisani, D; Precoma, DB; Saraiva, JF; Soares, RM | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD | 1 |
| Bao, W; Byun, YS; DeMicco, D; Laskey, R; Tsimikas, S; Witztum, JL; Yang, X | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Deedwania, P; Singh, V | 1 |
| Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM | 1 |
| Császár, A | 1 |
| Kim, YH; Kim, YJ; Lee, SH; Yoon, BW | 1 |
| Amarenco, P; Breazna, A; Callahan, A; Chaturvedi, S; Goldstein, LB; Hennerici, M; Rudolph, A; Sillesen, H; Welch, MA; Zivin, J | 1 |
| Fitchett, DH; Goodman, SG; Langer, A | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Martinez, DG | 1 |
| Caínzos Romero, T; Fernández Fernández, FJ; Pía Iglesias, G; Sesma, P | 1 |
| Hopkins, LN; Levy, EI; Samuelson, RM; Siddiqui, AH | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Hart, RG | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Coull, BM; Johnston, SC | 1 |
| Chen, TY; Kuo, YL; Lin, WC; Tan, TY | 1 |
| Amarenco, P; Brenner, D; Gongora-Rivera, F; Jaramillo, A; Klein, IF; Labreuche, J; Lavallée, PC; Touboul, PJ; Vicaut, E | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Karadağ, B; Ongen, Z; Yilmaz, Y | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Caro, JJ; Kongnakorn, T; O'Brien, JA; Proskorovsky, I; Roberts, CS; Ward, A | 1 |
| Welch, KM | 1 |
| Tsuda, K | 1 |
| Myint, PK; Niruban, A; Potter, JF | 1 |
| Castilla-Guerra, L; Chaturvedi, S; Fernandez-Moreno, Mdel C; Jimenez-Hernandez, MD | 1 |
| Chaturvedi, S; Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Chopp, M; Cui, Y; Jia, L; Lu, M; Zhang, L; Zhang, ZG | 1 |
| Landau, W | 1 |
| Strupp, M | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Nissen, SE | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Goldstein, LB; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, JA; Zweifler, RM | 1 |
| Cui, L; Du, W; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS | 1 |
| Huisa, BN; Stemer, AB; Zivin, JA | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Kamran, KA; Khan, M | 1 |
| Arrospide, A; Caro, J; Mar, J; Rejas-Gutiérrez, J; Vivancos-Mora, J | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Gaur, V; Kumar, A | 1 |
| Frey, P; Waters, DD | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Chen, YP; Chen, ZM; Feng, F; Jane, A; Jiang, LX; Li, J; Li, X; Martin, L | 1 |
| Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Kasner, SE; Taylor, RA; Weigele, JB | 1 |
| Sillence, D; Tchan, M | 1 |
| Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Ageno, W; Dentali, F; Romualdi, E; Squizzato, A | 1 |
| Braunwald, E | 1 |
| Shinohara, Y | 1 |
| Binning, MJ; Darkhabani, Z; Levy, EI; Mokin, M; Siddiqui, AH | 1 |
| Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Blanco, M; Castillo, J; Pérez-Mato, M; Rodríguez-Yáñez, M; Sobrino, T | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Munshi, A | 1 |
| Waeber, C; Wang, QM; Wei, Y; Zheng, Y | 1 |
| Degnan, AJ; Gillard, JH; Howarth, SP; Patterson, AJ; Tang, TY | 1 |
| Ali, S; Iyer, RS; Krishnan, M; Kumar, S | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Baumgartner, RW; Georgiadis, D | 1 |
| Clark, LT | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 3 |
| SoRelle, R | 1 |
| Chen, J; Chopp, M; Feldkamp, CS; Jiang, H; Katakowski, M; Li, Y; Lu, M; Wang, L; Wang, Y; Zhang, C; Zhang, ZG | 1 |
| Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, AS; Goldstein, L; Hennerici, M; Sillsen, H; Welch, MA; Zivin, J | 1 |
| Brown, WV; Moussa, M | 1 |
| Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK | 1 |
| Gathof, BS; Gresser, U | 1 |
| Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R | 1 |
| Hayashi, A; Ogawa, Y; Sasamata, M; Sonoda, R; Suzuki, M | 1 |
| Madsen, S | 1 |
| McGowan, MP | 1 |
| Chen, J; Chopp, M; Jiang, H; Katakowski, M; Li, Y; Lu, M; Robin, A; Zhang, C; Zhang, L | 1 |
| Griebenow, R | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Jaber, BL; Madias, NE | 1 |
| Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ | 1 |
| Clearfield, M | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Lesaffre, E; Rizopoulos, D; Tsonaka, R | 1 |
| Chopp, M; Ding, G; Ewing, JR; Jiang, Q; Li, L; Panda, S; Zhang, L; Zhang, ZG | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Kent, DM | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Carod-Artal, FJ | 1 |
| Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA | 1 |
| Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA | 1 |
| Cohen, JS | 1 |
| Khan, NA | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Elkind, MS | 1 |
| East, JE | 1 |
| Heering, NJ | 1 |
| Kulbertus, H | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC | 1 |
| Blanco, M; Castellanos, M; Castillo, J; Dávalos, A; García-Gil, M; Leira, R; Lizasoain, I; Moro, MA; Nombela, F; Rodriguez-Yáñez, M; Serena, J; Vivancos, J | 1 |
| Bassi, A; Caltagirone, C; Colivicchi, F; Santini, M | 1 |
| Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M | 1 |
| Arca, M | 1 |
| Arca, M; Gaspardone, A | 1 |
| Amarenco, P | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD | 1 |
| Armani, A; Toth, PP | 1 |
| Chen, J; Chopp, M; Cui, X; Li, A; Lu, M; Roberts, C; Zacharek, A | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Bonnaire, B; Bugnicourt, JM; Garcia, PY; Godefroy, O; Lefranc, M; Lepage, L | 1 |
| Crook, MA; Mikhailidis, DP; Wierzbicki, AS; Winder, AF | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Basson, CT; Delanty, N; Vaughan, CJ | 1 |
27 review(s) available for atorvastatin and Stroke
| Article | Year |
|---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Ceftriaxone; Dibenzazepines; Drug Repositioning; Epilepsy; Epilepsy, Post-Traumatic; Erythropoietin; Fingolimod Hydrochloride; GABA Agents; Gabapentin; Humans; Immunologic Factors; Inflammation; Interleukin 1 Receptor Antagonist Protein; Isoflurane; Levetiracetam; Losartan; Neuroprotective Agents; Oxidative Stress; Pregabalin; Pyrrolidinones; Sirolimus; Stroke; Topiramate; Translational Research, Biomedical; Vigabatrin | 2020 |
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
[Statins after intracerebral haemorrhage: is this safe?].
Topics: Atorvastatin; Cerebral Hemorrhage; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Stroke | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
What's new in stroke? The top 10 studies of 2006-2008. Part II.
Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2008 |
[Atorvastatin in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke | 2009 |
Review of the SPARCL trial and its subanalyses.
Topics: Age Factors; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrroles; Risk Factors; Sex Factors; Stroke | 2009 |
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke | 2010 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Pathologic; Endovascular Procedures; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Stents; Stroke; Tetrazoles | 2011 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Neuroprotective Agents; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Ticlopidine | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator | 2010 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Smoking Prevention; Stents; Stroke; Vertebral Artery Dissection | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2004 |
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2005 |
Stroke prevention, blood cholesterol and statins.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke | 2005 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2006 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Atorvastatin: its clinical role in cerebrovascular prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke | 2007 |
Atorvastatin in prevention of stroke and transient ischaemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2007 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Statin therapy and stroke prevention.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Encephalitis; Endothelium, Vascular; Fibrinolytic Agents; Heptanoic Acids; Humans; Lovastatin; Nitric Oxide Synthase; Pyrroles; Stroke | 2001 |
69 trial(s) available for atorvastatin and Stroke
| Article | Year |
|---|---|
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Ischemic Stroke; Middle Aged; Platelet Aggregation Inhibitors; Stroke | 2023 |
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
Topics: Adult; Atorvastatin; Cataract; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome; Young Adult | 2023 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Stroke; Treatment Outcome | 2020 |
The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke.
Topics: Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery, Common; Carotid Intima-Media Thickness; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Prospective Studies; Risk Factors; Stroke | 2020 |
Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Calcitonin; Cross Infection; Female; Glasgow Coma Scale; Humans; Inflammation; Intensive Care Units; Interleukin-6; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Stroke; Tumor Necrosis Factor-alpha | 2017 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Topics: Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Care Planning; PCSK9 Inhibitors; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2017 |
Intensive Statin Therapy for Acute Ischemic Stroke to Reduce the Number of Microemboli: A Preliminary, Randomized Controlled Study.
Topics: Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Middle Aged; Stroke; Ultrasonography, Doppler | 2018 |
Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke.
Topics: Adult; Aged; Aspirin; Atorvastatin; Chlorpromazine; Double-Blind Method; Drug Therapy, Combination; Edaravone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Platelet Aggregation Inhibitors; Promethazine; Stroke; Vinca Alkaloids | 2019 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases | 2014 |
Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.
Topics: Aged; Atorvastatin; China; Clinical Protocols; Constriction, Pathologic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pyrroles; Single-Blind Method; Stroke; Vertebrobasilar Insufficiency | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Topics: Aged; Atorvastatin; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kidney; Male; Middle Aged; Pyrroles; Stroke | 2014 |
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography | 2015 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke | 2015 |
Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial.
Topics: Acute Disease; Aged; Atorvastatin; Biomarkers; Brain Ischemia; E-Selectin; Female; Humans; Inflammation; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interleukin-10; Interleukin-1beta; Interleukin-6; Intracranial Arteriosclerosis; Male; Middle Aged; P-Selectin; Stroke; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
[Perioperative intensive statin therapy improves outcomes in patients with ischemic stroke undergoing middle cerebral artery stent implantation].
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Basigin; C-Reactive Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Cerebral Artery; Stents; Stroke; Vascular Cell Adhesion Molecule-1 | 2016 |
Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
Topics: Aged; Asymptomatic Diseases; Atorvastatin; Biomarkers; Comorbidity; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Prevalence; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2016 |
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
Topics: Aged; Atorvastatin; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Perioperative Care; Postoperative Complications; Proportional Hazards Models; Risk Assessment; Stroke; Surgical Procedures, Operative; Troponin | 2017 |
Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Phospholipids; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke | 2017 |
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides | 2008 |
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides | 2009 |
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult | 2009 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Stroke | 2010 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase.
Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Nitric Oxide; Pyrroles; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Stroke | 2003 |
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
High-dose atorvastatin after stroke or transient ischemic attack.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke | 2006 |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2007 |
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
Topics: Acute Disease; Aged; Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Odds Ratio; Pyrroles; Risk Factors; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Withholding Treatment | 2007 |
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2007 |
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke | 2008 |
SPARCL: the glimmer of statins for stroke risk reduction.
Topics: Atorvastatin; Coronary Disease; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2007 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
141 other study(ies) available for atorvastatin and Stroke
| Article | Year |
|---|---|
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Evaluation of the Effects of Folic Acid Combined with Atorvastatin on the Poststroke Cognitive Impairment by Low-Rank Matrix Denoising Algorithm-Based MRI Imaging.
Topics: Algorithms; Atorvastatin; Cognitive Dysfunction; Folic Acid; Humans; Ischemic Stroke; Magnetic Resonance Imaging; Stroke | 2022 |
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.
Topics: Anticoagulants; Asian People; Atorvastatin; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Rivaroxaban; Simvastatin; Singapore; Stroke | 2023 |
Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care.
Topics: Adult; Atorvastatin; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Cerebral Infarction; Humans; Hypertension; Retrospective Studies; Stroke; Tablets | 2022 |
Is statin therapy after ischaemic stroke associated with increased intracerebral hemorrhage? The association may be dependent on intensity of statin therapy.
Topics: Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Rosuvastatin Calcium; Simvastatin; Stroke | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Low-density lipoprotein cholesterol, statin therapy, and cerebral microbleeds: The CIRCLE study.
Topics: Atorvastatin; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2023 |
Oatp (Organic Anion Transporting Polypeptide)-Mediated Transport: A Mechanism for Atorvastatin Neuroprotection in Stroke.
Topics: Animals; Atorvastatin; Brain Edema; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Neuroprotection; Neuroprotective Agents; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; Stroke | 2023 |
Letter to the editor concerning coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin.
Topics: Animals; Atorvastatin; Dietary Supplements; Rats; Stroke; Ubiquinone | 2021 |
Effect of high-dose strong statin for preventing periprocedural ischemic complications of carotid artery stenting.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Artery Diseases; Diffusion Magnetic Resonance Imaging; Drug Administration Schedule; Endovascular Procedures; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Stents; Stroke; Time Factors; Treatment Outcome | 2020 |
Caught in a Flare.
Topics: Arthralgia; Aspirin; Atorvastatin; Brain; Diagnosis, Differential; Exanthema; Fatigue; Female; Hematologic Tests; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Nervous System Diseases; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Young Adult | 2020 |
Intracerebral Hemorrhage in SPARCL: What Was the Relationship to LDL-C?
Topics: Atorvastatin; Cerebral Hemorrhage; Cholesterol, LDL; Humans; Stroke | 2020 |
Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond.
Topics: Atorvastatin; Cholesterol, LDL; Hemorrhagic Stroke; Humans; Ischemic Attack, Transient; Stroke | 2020 |
Effect of atorvastatin on expression of TLR4 and NF-κB in stroke rats and its protective effect on brain.
Topics: Administration, Oral; Animals; Atorvastatin; Brain; NF-kappa B; Protective Agents; Rats; Rats, Sprague-Dawley; Stroke; Toll-Like Receptor 4 | 2020 |
Atorvastatin alleviates microglia-mediated neuroinflammation via modulating the microbial composition and the intestinal barrier function in ischemic stroke mice.
Topics: Animals; Atorvastatin; Brain Ischemia; Ischemic Stroke; Mice; Mice, Inbred C57BL; Microglia; Stroke | 2021 |
Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Aspirin; Atorvastatin; Cerebral Infarction; Drug Therapy, Combination; Epilepsy; Female; Humans; Levetiracetam; Male; Severity of Illness Index; Stroke | 2020 |
Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke.
Topics: Animals; Atorvastatin; Blood-Brain Barrier; Brain Ischemia; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Pericytes; Rats; Stroke; Vascular Remodeling | 2021 |
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombosis | 2021 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Dementia; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk Factors; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2021 |
Lights Out: An Unusual Case of Amaurosis Fugax.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Anticholesteremic Agents; Arterial Occlusive Diseases; Aspirin; Atorvastatin; Brachiocephalic Trunk; Clopidogrel; Computed Tomography Angiography; Drug Therapy, Combination; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Stents; Stroke; Vertigo | 2018 |
Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; Brain Ischemia; Encephalitis; Male; Neuroprotective Agents; Oxidative Stress; Rats, Wistar; Stroke; Treatment Outcome; Ubiquinone | 2019 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Internal; Computed Tomography Angiography; Female; Fibromuscular Dysplasia; Humans; Hyperplasia; Neointima; Recurrence; Risk Factors; Stroke | 2018 |
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2018 |
Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population.
Topics: Aged; Alleles; Asian People; Atorvastatin; Brain Ischemia; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Stroke | 2018 |
Artery of Percheron: an unusual stroke presentation.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Cerebral Arteries; Clopidogrel; Diagnosis, Differential; Female; Humans; Magnetic Resonance Imaging; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Vascular Malformations | 2018 |
Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study.
Topics: Aged; Atorvastatin; Epilepsy; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Seizures; Stroke; Taiwan | 2018 |
Anterior spinal cord infarct: a rare yet disabling stroke.
Topics: Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Diagnosis, Differential; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Platelet Aggregation Inhibitors; Rare Diseases; Spinal Cord; Spinal Cord Ischemia; Stroke; Stroke Rehabilitation; Ticlopidine; Treatment Outcome | 2018 |
Assessment of the MRI and Behavioral Test Results in a Focal Cerebral Ischemia-Reperfusion Model in the Rat after Separate and Combined Use of Mouse-Derived Neural Progenitor Cells, Human-Derived Neural Progenitor Cells and Atorvastatin.
Topics: Animals; Atorvastatin; Behavior Rating Scale; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Mice; Neural Stem Cells; Rats; Recovery of Function; Reperfusion Injury; Stroke | 2018 |
Ischemic stroke following a wasp sting - a rare complication: a case report.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Brain; Brain Ischemia; Humans; Insect Bites and Stings; Magnetic Resonance Imaging; Male; Stroke; Wasps | 2018 |
Behavioural changes as the first manifestation of a silent frontal lobe stroke.
Topics: Aged; Atorvastatin; Brain; Cerebral Infarction; Frontal Lobe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Neuroimaging; Problem Behavior; Stroke; Syndrome; Tomography, X-Ray Computed | 2019 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Brain; Brain Ischemia; Cranial Nerve Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Middle Aged; Paresis; Physical Therapy Modalities; Platelet Aggregation Inhibitors; Ramipril; Stroke; Syndrome | 2019 |
Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.
Topics: Aged; Asian People; Atorvastatin; Brain Ischemia; China; Cytochrome P-450 CYP3A; Disability Evaluation; Female; Gene Frequency; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Recovery of Function; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2019 |
Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Brain Ischemia; Case-Control Studies; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Polymorphism, Single Nucleotide; Stroke | 2019 |
Sphingolipidomics Investigation of the Temporal Dynamics after Ischemic Brain Injury.
Topics: Animals; Atorvastatin; Brain; Brain Injuries; Brain Ischemia; Ceramides; Chromatography, High Pressure Liquid; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Lipidomics; Lysophospholipids; Mice; Sphingolipids; Sphingosine; Stroke; Tandem Mass Spectrometry | 2019 |
Delusional parasitosis as presenting symptom of occipital lobe cerebrovascular accident.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Delusional Parasitosis; Female; Humans; Middle Aged; Neuroimaging; Occipital Lobe; Pruritus; Stroke; Treatment Outcome | 2019 |
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography | 2014 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
Topics: Animals; Atorvastatin; Cerebral Cortex; Disease Models, Animal; Gene Expression; Heptanoic Acids; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase Type II; PPAR alpha; Pyrroles; Stroke; Vascular Cell Adhesion Molecule-1 | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Life Style; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2014 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome | 2015 |
Ask the doctor. I am 61 and had been on atorvastatin for 10 years with no problems. Recently, I've had disabling muscle pain with both the generic atorvastatin and the brand-name version, Lipitor. My doctor says that I can no longer take statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Health Behavior; Heptanoic Acids; Humans; Middle Aged; Muscle, Skeletal; Pyrroles; Rhabdomyolysis; Stroke | 2014 |
Statin treatment reduces the risk of poststroke seizures.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brain Ischemia; Cohort Studies; Epilepsy; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rosuvastatin Calcium; Seizures; Simvastatin; Stroke; Time Factors; Treatment Outcome | 2015 |
Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia.
Topics: Animals; Atorvastatin; Brain; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Stroke | 2015 |
Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2015 |
Statins Promote Long-Term Recovery after Ischemic Stroke by Reconnecting Noradrenergic Neuronal Circuitry.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain Ischemia; Cell Proliferation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Locus Coeruleus; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neurogenesis; Recovery of Function; Stroke; Sympathetic Nervous System | 2015 |
Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Early Medical Intervention; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Risk Factors; Stroke; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2016 |
Atorvastatin attenuates cognitive deficits through Akt1/caspase-3 signaling pathway in ischemic stroke.
Topics: Animals; Atorvastatin; Brain Ischemia; Caspase 3; Cognition Disorders; Male; Maze Learning; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Stroke | 2015 |
Effect of atorvastatin co-treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Activation; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2015 |
Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Brain-Derived Neurotrophic Factor; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Outcome Assessment, Health Care; Recovery of Function; Stroke | 2017 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
[Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack].
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Retrospective Studies; Stroke | 2016 |
Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-V; Atorvastatin; Brain Ischemia; Cholesterol Ester Transfer Proteins; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl CoA Reductases; Lipoprotein Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Stroke | 2016 |
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
Topics: Acute Coronary Syndrome; Aged; American Heart Association; Angina, Unstable; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Female; Guideline Adherence; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Societies, Medical; Stroke; United States | 2016 |
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke | 2017 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Atorvastatin enhances hypothermia-induced neuroprotection after stroke.
Topics: Animals; Atorvastatin; Brain Infarction; CD11b Antigen; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnetic Resonance Imaging; Male; Neurologic Examination; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stroke | 2008 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Risk Assessment; Stroke | 2009 |
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2008 |
Hemorrhagic stroke in the SPARCL study.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intracranial Hemorrhages; Lipoproteins, LDL; Male; Pyrroles; Risk Factors; Stroke | 2008 |
Binder wars.
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke | 2008 |
[Statins and stroke].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Neovascularization, Physiologic; Pyrroles; Stroke | 2008 |
The cost of stroke prevention.
Topics: Atorvastatin; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
Statins: not just for the young or the faint of heart.
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Computer Simulation; Cost-Benefit Analysis; Databases, Factual; Female; Health Services; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Saskatchewan; Secondary Prevention; Stroke; Survival Analysis; United States; Young Adult | 2009 |
Statins and gender-related difference in endothelial function in cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Heptanoic Acids; Humans; Ischemic Attack, Transient; Outcome Assessment, Health Care; Pyrroles; Stroke; Treatment Outcome | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Hemorrhage; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Iatrogenic Disease; Ischemic Attack, Transient; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2009 |
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Heptanoic Acids; Immunohistochemistry; Intracranial Embolism; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Stroke; Time Factors; Tissue Plasminogen Activator | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Secondary Prevention; Stroke | 2009 |
The results support the use of atorvastatin in elderly patients with recent stroke or TIA.
Topics: Aged; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Stroke | 2009 |
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
Topics: Acute Disease; Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Capillary Permeability; Down-Regulation; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phospholipases A2, Cytosolic; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke; Time Factors | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Topics: Age Factors; Aged; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Stroke; Treatment Outcome | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
Topics: Atorvastatin; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pakistan; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2010 |
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Models, Theoretical; Myocardial Infarction; Placebos; Pyrroles; Risk Factors; Secondary Prevention; Spain; Stroke; Treatment Outcome; Young Adult | 2010 |
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Male; Neurons; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria; Motor Activity; Movement Disorders; Neurons; Organ Specificity; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Stroke; Tetrazoles | 2011 |
Statins before stents: does an ounce of prevention improve outcomes?
Topics: Atorvastatin; Biomarkers; Carotid Artery Diseases; Creatine Kinase, MB Form; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome; Troponin I; Troponin T | 2010 |
[A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China].
Topics: Atorvastatin; China; Cross-Sectional Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2010 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid Stenosis; Clopidogrel; Colitis, Ulcerative; Female; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Lipoprotein(a); Magnetic Resonance Imaging; Middle Aged; Pyrroles; Risk Factors; Stroke; Thrombosis; Ticlopidine; Ultrasonography | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Stroke | 2012 |
Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature.
Topics: Aspirin; Atorvastatin; Craniotomy; Echocardiography, Transesophageal; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Intracranial Aneurysm; Intracranial Embolism; Male; Middle Aged; Neurosurgical Procedures; Paresis; Pyrroles; Stroke; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Ischemia; Lipoprotein Lipase; Male; Middle Aged; Minisatellite Repeats; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Pyrroles; Risk Factors; Stroke | 2012 |
Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice.
Topics: Animals; Atorvastatin; Behavior, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuropsychological Tests; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrroles; Recovery of Function; Sildenafil Citrate; Stroke; Sulfones | 2013 |
Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: follow-up of the ATHEROMA trial.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Contrast Media; Dextrans; Diabetes Complications; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Macrophage Activation; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2012 |
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Anterior Cerebral Artery; Magnetic Resonance Angiography; Male; Platelet Aggregation Inhibitors; Pyrroles; Stroke | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom | 2002 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
Withdrawal of statin treatment abrogates stroke protection in mice.
Topics: Animals; Aorta; Atorvastatin; Bleeding Time; Blood Coagulation; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Stroke; Substance Withdrawal Syndrome; Vena Cava, Inferior; Venous Thrombosis | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke.
Topics: Animals; Antibodies; Atorvastatin; Brain; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neovascularization, Physiologic; Neuronal Plasticity; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Stroke; Synapses; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone | 2004 |
Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat.
Topics: Animals; Atorvastatin; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Pyrroles; Rats; Rats, Inbred SHR; Stroke | 2004 |
[Statins and hypertension].
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.
Topics: Animals; Atorvastatin; Brain-Derived Neurotrophic Factor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Neovascularization, Physiologic; Neuronal Plasticity; Pyrroles; Rats; Recovery of Function; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2005 |
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2005 |
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
The logistic transform for bounded outcome scores.
Topics: Anticholesteremic Agents; Atorvastatin; Computer Simulation; Coronary Disease; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Tissue Plasminogen Activator | 2007 |
MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Data Interpretation, Statistical; Heptanoic Acids; Intracranial Embolism; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Microcirculation; Microscopy, Fluorescence; Plasminogen Activators; Pyrroles; Rats; Rats, Wistar; Recombinant Proteins; Stroke | 2006 |
[After TIA and stroke: a statin for secondary prevention?].
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Placebos; Pyrroles; Recurrence; Stroke; Time Factors | 2006 |
Stroke--an equal opportunity for the initiation of statin therapy.
Topics: Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Stroke | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Atorvastatin for stroke prevention.
Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Severity of Illness Index; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Conflict of Interest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis | 2006 |
Statin effective in preventing recurrent stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Stroke | 2006 |
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
Discontinuation of statin therapy and clinical outcome after ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Simvastatin; Stroke; Substance Withdrawal Syndrome | 2007 |
Higher dose of statin medication may be better for older adults.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Stroke | 2007 |
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Disease Models, Animal; Heptanoic Acids; Homeodomain Proteins; Male; Middle Cerebral Artery; Neurons; Presenilin-1; Pyrroles; Rats; Rats, Wistar; Receptor, Notch1; Signal Transduction; Stem Cells; Stroke; Transcription Factor HES-1 | 2008 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvastatin; Calcinosis; Heptanoic Acids; Humans; Intracranial Embolism; Male; Pyrroles; Stroke; Tomography, X-Ray Computed | 2008 |
Natural statins and stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fibrinogen; Heptanoic Acids; Humans; Pyrroles; Risk Factors; Stroke | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |